Cross-linked polymer modified nanoparticles

Patent metadata

Field	Value
Publication number	US-11207428-B2
Application number	US-201715429971-A
Country	US
Kind code	B2
Filing date	Feb 10, 2017
Priority date	Mar 16, 2015
Publication date	Dec 28, 2021
Grant date	Dec 28, 2021

Abstract

Disclosed herein are nanoconstructs comprising a nanoparticle, coated with additional agents such as cationic polymers, stabilizers, targeting molecules, labels, oligonucleotides and small molecules. These constructs may be used to deliver compounds to treat solid tumors and to diagnose cancer and other diseases. Further disclosed are methods of making such compounds and use of such compounds to treat or diagnose human disease.

First claim

The invention claimed is:

1. A pharmaceutical composition comprising:
a plurality of multilayer nanoconstructs comprising:
about 10% to about 30% by weight cross-linked polyethylenimine (PEI) bound to an exterior surface of a nanoparticle, wherein the nanoparticle comprises silica, silicon, iron oxide, silver, or a carbon nanotube; and
polyethylene glycol (PEG) bound to the PEI or to the nanoparticle;
wherein the nanoconstructs have a hydrodynamic size Z-average diameter of about 200 nm or less and the plurality of nanoconstructs have a polydispersity index (PDI) of no more than about 0.37;

an oligonucleotide non-covalently attached to the PEI; and
a pharmaceutically acceptable carrier.

2. The pharmaceutical composition of claim 1 , wherein the nanoparticle of the nanoconstructs is a silica nanoparticle.

3. The pharmaceutical composition of claim 1 , wherein the PEI of the nanoconstructs is from about 10% to about 25% by weight of the nanoconstructs.

4. The pharmaceutical composition of claim 1 , wherein the oligonucleotide is electrostatically bound to the PEI.

5. The pharmaceutical composition of claim 1 , wherein the plurality of nanoconstructs further comprises a small molecule or a protein.

6. The pharmaceutical composition of claim 5 , wherein the small molecule is a chemotherapeutic agent, small molecule inhibitor, label or a polypeptide.

7. The pharmaceutical composition of claim 1 , wherein the plurality of nanoconstructs further comprises a targeting agent.

8. The pharmaceutical composition of claim 1 , further comprising trehalose.

9. The pharmaceutical composition of claim 8 , wherein the trehalose is from about 1% to about 10% by weight of the plurality of nanoconstructs.

10. The pharmaceutical composition of claim 1 , wherein the pharmaceutically acceptable carrier is aqueous.

11. The pharmaceutical composition of claim 1 , wherein the pharmaceutically acceptable carrier is non-aqueous.

12. The pharmaceutical composition of claim 1 , wherein the composition is an emulsion, gel, or ointment.

13. The pharmaceutical composition of claim 6 , wherein the small molecule is a chemotherapeutic agent.

14. The pharmaceutical composition of claim 1 , wherein the nanoparticle is from about 10 nm to about 90 nm in diameter.

15. The pharmaceutical composition of claim 1 , wherein the hydrodynamic size Z-average diameter of the nanoconstructs is about 80 nm to about 200 nm.

16. The pharmaceutical composition of claim 1 , wherein the hydrodynamic size Z-average diameter of the nanoconstructs is about 90 nm to about 120 nm.

17. The pharmaceutical composition of claim 1 , wherein the PEI is crosslinked using a cleavable crosslinker.

18. The pharmaceutical composition of claim 1 , wherein the PDI of the nanoconstructs is about 0.22.

19. The pharmaceutical composition of claim 1 , wherein the PEI has an average size of 1.8 kDa to 25 kDa.

20. The pharmaceutical composition of claim 5 , wherein the protein comprises an antibody or antibody fragment.

21. The pharmaceutical composition of claim 1 , wherein oligonucleotide comprises at least one of siRNA, miRNA, an miRNA mimic, DNA, or an antisense oligomer.

22. The pharmaceutical composition of claim 21 , wherein the hydrodynamic diameter of the nanoconstructs loaded with the siRNA is about 200 nm or less.

23. The pharmaceutical composition of claim 21 , wherein the PDI of the nanoconstructs loaded with the siRNA is no more than about 0.37.

24. The pharmaceutical composition of claim 21 , wherein the PDI of the nanoconstructs loaded with the siRNA is no more than about 0.2.

25. The pharmaceutical composition of claim 1 , wherein the oligonucleotide comprises siRNA.

26. The pharmaceutical composition of claim 1 , wherein the oligonucleotide comprises miRNA.

27. The pharmaceutical composition of claim 1 , wherein the oligonucleotide comprises an miRNA mimic.

28. The pharmaceutical composition of claim 1 , wherein the oligonucleotide comprises DNA.

29. The pharmaceutical composition of claim 1 , wherein the oligonucleotide comprises an antisense oligomer.

30. The pharmaceutical composition of claim 1 , wherein the nanoparticle of the nanoconstructs is a silicon nanoparticle.

31. The pharmaceutical composition of claim 1 , wherein the nanoparticle of the nanoconstructs is an iron oxide nanoparticle.

32. The pharmaceutical composition of claim 1 , wherein the nanoparticle of the nanoconstructs is a silver nanoparticle.

33. The pharmaceutical composition of claim 1 , wherein the nanoparticle of the nanoconstructs is a carbon nanotube.

34. The pharmaceutical composition of claim 2 , wherein the silica nanoparticle is a mesoporous silica nanoparticle (MSNP).

35. A method of delivering an oligonucleotide to a site in a human or other mammalian subject comprising administering an effective amount of the pharmaceutical composition of claim 1 to the human or other mammalian subject under conditions to deliver the nanoconstruct to the site.

36. The method of claim 34 , wherein the site is a cell.

37. The method of claim 36 , wherein the nanoconstruct is administered under conditions that the nanoconstruct is internalized by the cell.

38. The method of claim 35 , wherein the oligonucleotide is capable of modulating expression of a target protein.

39. The method of claim 35 , wherein the subject is diagnosed with cancer or diagnosed with or is at risk for fibrosis or inflammation, and the effective amount is a therapeutically effective amount.

40. The method of claim 35 , wherein the nanoconstruct further comprises a targeting agent.

41. The method of claim 35 , wherein the nanoconstruct reduces reactive oxygen species, bioavailable copper, and/or NOX expression level in the subject or modulates an adverse effect of one or more cytokines.

42. A method of labeling a target comprising contacting the pharmaceutical composition of claim 1 with the target under conditions to bind the nanoconstruct to the target.

43. The method of claim 42 , wherein the nanoconstruct is labeled with a lanthanide, a fluorescent dye, a gold nanoparticle, a quantum dot, a PET tracer, or a MRI contrast agent.

44. The method of claim 43 , further comprising quantifying the amount of target by detecting the label after the nanoconstruct binds to the target or administering the labeled nanoconstruct to a subject and detecting the location of the label after the administering.

Assignees

• Pdx Pharmaceuticals Inc
• Univ Oregon Health & Science

Inventors

• Yantasee Wassana
• Ngamcherdtrakul Worapol
• Morry Jingga
• Castro David
• Gray Joe

Classifications

• A61K31/713 Primary

  Double-stranded nucleic acids or oligonucleotides · CPC title

• A61K49/186

  the organic macromolecular compound being polyethyleneglycol [PEG] · CPC title

• A61K49/1875

  coated or functionalised with an antibody · CPC title

• A61K47/551

  one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid · CPC title

• A61K47/59

  obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes · CPC title